Investor Pack
Alpina Bio AG. Template v1. Edit by typing an instruction; approve the diff before anything changes.
Position
Use of funds versus plan
| Group | Planned | Actual | Delta |
|---|---|---|---|
| Product and production | CHF 172,610.47 | CHF 169,532.64 | CHF -3,077.83 |
| People | CHF 178,000.00 | CHF 175,000.00 | CHF -3,000.00 |
| Go to market | CHF 47,904.00 | CHF 44,980.59 | CHF -2,923.41 |
| Operations | CHF 21,686.08 | CHF 22,250.93 | CHF 564.85 |
| Capital expenditure | CHF 0.00 | CHF 0.00 | CHF 0.00 |
Twelve month liquidity curve
Commentary
Net burn held within 4 percent of plan. The clinical study remains the largest single driver and winds down from October 2027.
Lab consumables ran 22 percent over for a second month. Carried forward at the observed rate, this costs 11 days of runway. Worth a supplier conversation before the next order.
Subscriber base and referral orders grew in line with the rebased plan. The next production batch is funded and ordered.
Edit by chat
Built in commands: shorten, remove, retitle, add a line. Free instructions use the language model when a key is configured. Nothing changes until you approve the diff.
Branding
Applied to the preview and the PDF instantly. Alpina Bio ships preloaded.